VIB INKS QBASE+ GROUP LICENSING AGREEMENT WITH BIOGAZELLE: http://t.co/EkimyQQSZW
posted
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
In just 15 years after commercialization, accumulated biotech crops exceeded 1 billion hectares in 2010, a milestone that signifies biotech crops are here to stay, according to Clive James author of the annual report released by ISAAA. read more
Promethera® Biosciences an innovative stem cell therapy company dedicated to liver regenerative medicine announces that Dr. Beatrice De Vos joined the company to lead its Clinical Research & Medical Affairs team. She joined Promethera® Biosciences SA from January 1, 2011 as Chief Medical Officer. read more
TiGenix (NYSE EURONEXT: TIG) announces the reimbursement approval of ChondroCelect in Belgium by the Minister of Social Affairs within a convention and provides a reimbursement update for other European countries. read more
TiGenix NV (NYSE Euronext Brussels: TIG) and Cellerix SA, a privately held company based in Spain, announce that the two cell therapy-focused biotechnology companies and Cellerix' shareholders have entered into a contribution agreement to combine the operations of both companies by means of a share for share exchange. read more
PharmaNeuroBoost NV (PNB) reported today that both the U.S. Patent and Trade Office (USPTO) and Japanese Patent Office (JPT) granted the patent application of its lead product PNB01, a fixed dose combination of citalopram and low dose pipamperone, as a pharmaceutical composition of matter, for treating a mood disorder or an anxiety disorder. read more
Pharmaneuroboost (PNB) reported today that the design of its pivotal Phase III studies with PNB01 in Major Depressive Disorder (MDD) will be presented at the 51st NCDEU Conference held June 13-16 in Boca Raton, Florida. read more
Pronota NV today announced that it has entered into an agreement with Molecuence Corporation, a wholly owned subsidiary of Mitsubishi Chemical Corporation, to discover and validate protein biomarkers in stroke. Pronota will apply its proven proprietary platforms for protein biomarker discovery (MASStermind®) and biomarker verification (MASSterclass™) to this project. The financial terms have not been disclosed. read more
